
    
      This is a Phase II, prospective, randomized, double-blinded (investigator/site staff and
      participants; Sponsor open), dose-comparison, multi-center study. Participants who are
      generally healthy or with stable pre-existing health conditions will be randomized,
      stratified by comorbidity. All eligible participants will be randomized to receive 2 doses of
      either High-dose or Mid-dose of MVC-COV190 in a predefined ratio.
    
  